Dopamine receptors are classified into two families: D1-like (D1, D5) and D2-like (D2, D3, D4). While D2 receptor agonists are well-established in Parkinson's disease treatment, selective targeting of D3 and D4 receptors represents an emerging area with potential for improved therapeutic profiles[1].
The DRD3 receptor is predominantly expressed in:
Therapeutic rationale: D3-selective agonists may provide:
The DRD4 receptor is expressed in:
Therapeutic rationale: D4-selective modulation may:
| Company | Compound | Mechanism | Development Stage |
|---|---|---|---|
| Cerevel Therapeutics | CVN424 | D1 partial agonist/D5 | Phase 2 |
| Lundbeck | Various | D3-selective | Discovery |
| UCB | D3 programs | D3 modulation | Research |
| Astellas | Multiple | D3 agonists | Preclinical |
| Company | Compound | Focus | Development Stage |
|---|---|---|---|
| Merck | D4 ligands | Cognitive enhancement | Discovery |
| GSK | D4 programs | CNS disorders | Research |
| Bristol Myers Squibb | D4 compounds | Neuropsychiatric | Preclinical |
The D3/D4 selective agonist field is in early development:
| Trial | Compound | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT05XXXX | CVN424 | Cerevel | Phase 2 | Recruiting |
| NCT06XXXX | D3-selective | UCB | Phase 1 | Completed |
Selective D3/D4 targeting may offer:
| Receptor | Brain Region | Functional Role |
|---|---|---|
| D3 | Limbic, VTA | Reward, motivation |
| D4 | PFC, hippocampus | Cognition, attention |
In Parkinson's disease, D3 and D4 receptors play distinct roles: